Molecular mechanisms of methoctramine binding and selectivity at muscarinic acetylcholine receptors
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24870405
DOI
10.1124/mol.114.093310
PII: S0026-895X(24)03960-9
Knihovny.cz E-resources
- MeSH
- Diamines metabolism MeSH
- DNA Topoisomerases, Type I genetics metabolism MeSH
- Heterocyclic Compounds, 4 or More Rings pharmacology MeSH
- Isoquinolines pharmacology MeSH
- Binding, Competitive drug effects physiology MeSH
- Coumarins pharmacology MeSH
- Humans MeSH
- DNA, Mitochondrial genetics MeSH
- Mitochondria drug effects genetics metabolism MeSH
- Cell Line, Tumor MeSH
- Receptors, Muscarinic genetics metabolism MeSH
- Binding Sites drug effects physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Diamines MeSH
- DNA Topoisomerases, Type I MeSH
- Heterocyclic Compounds, 4 or More Rings MeSH
- Isoquinolines MeSH
- Coumarins MeSH
- lamellarin D MeSH Browser
- methoctramine MeSH Browser
- DNA, Mitochondrial MeSH
- Receptors, Muscarinic MeSH
- TOP1 protein, human MeSH Browser
Methoctramine (N,N'-bis[6-[[(2-methoxyphenyl)-methyl]hexyl]-1,8-octane] diamine) is an M(2)-selective competitive antagonist of muscarinic acetylcholine receptors and exhibits allosteric properties at high concentrations. To reveal the molecular mechanisms of methoctramine binding and selectivity we took advantage of reciprocal mutations of the M(2) and M(3) receptors in the second and third extracellular loops that are involved in the binding of allosteric ligands. To this end we performed measurements of kinetics of the radiolabeled antagonists N-methylscopolamine (NMS) in the presence of methoctramine and its precursors, fluorescence energy transfer between green fluorescent protein-fused receptors and an Alexa-555-conjugated precursor of methoctramine, and simulation of molecular dynamics of methoctramine association with the receptor. We confirm the hypothesis that methoctramine high-affinity binding to the M(2) receptors involves simultaneous interaction with both the orthosteric binding site and the allosteric binding site located between the second and third extracellular loops. Methoctramine can bind solely with low affinity to the allosteric binding site on the extracellular domain of NMS-occupied M(2) receptors by interacting primarily with glutamate 175 in the second extracellular loop. In this mode, methoctramine physically prevents dissociation of NMS from the orthosteric binding site. Our results also demonstrate that lysine 523 in the third extracellular loop of the M(3) receptors forms a hydrogen bond with glutamate 219 of the second extracellular loop that hinders methoctramine binding to the allosteric site at this receptor subtype. Impaired interaction with the allosteric binding site manifests as low-affinity binding of methoctramine at the M(3) receptor.
References provided by Crossref.org
Current Advances in Allosteric Modulation of Muscarinic Receptors
Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators
Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation
Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors